1. Home
  2. Team
  3. Thomas Casdagli

Thomas joined MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers’ Private Equity and Venture Capital practice. Thomas has an MBioch in Molecular and Cellular Biochemistry from Oxford University.

Thomas is a member of the boards of eXmoor Pharma Concepts Ltd, icotec AG and eZono GmbH. He was previously a director of Valneva SE (EPA: VLA), Alliance Pharma plc (AIM:APH), Lombard Medical Technologies plc (NASDAQ:EVAR), Heptares Ltd (acquired by Sosei Group Corporation), Avantium BV (AMS:AVTX), Onbone Oy, and Xention Pharma.

Latest news

OSSIO Raises $27.6 Million to Accelerate Its Commercial Engine as High Demand for Bio-Integrative Fixation Technology Continues
December 2, 2024
Hologic agrees to acquire Gynesonics
October 14, 2024
eXmoor Pharma Partners with Quell Therapeutics to Develop CAR-Treg Cell Therapies
September 24, 2024
Stryker agrees to acquire Vertos Medical
August 22, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
August 20, 2024
Providence Medical Technology, Inc. Announces FDA Clearance of CORUS™ Navigation Access System for Use with Medtronic’s StealthStation™ Surgical Navigation in Posterior Spinal Fusion
June 13, 2024
Nalu PNS System achieves significant and durable pain reduction, meeting the primary endpoint of the COMFORT RCT study
June 4, 2024
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
April 15, 2024
Optinose’s XHANCE® Approved by FDA for Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024
GT Medical Technologies Names Per Langoe As CEO
February 20, 2024
View all